Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

4.350 -0.110 (-2.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 74,165
Open 4.400
Bid (Size) 4.300 (11)
Ask (Size) 4.490 (50)
Prev. Close 4.460
Today's Range 4.340 - 4.530
52wk Range 3.620 - 9.180
Shares Outstanding 72,407,215
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study
Kezar Life Sciences' zetomipzomib trial in autoimmune hepatitis resumes as FDA lifts partial hold following a favorable safety review. 
Via Benzinga
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
From Kezar Life Sciences, Inc.
Via Business Wire

Performance

YTD
-33.8%
-33.8%
1 Month
-2.5%
-2.5%
3 Month
+4.8%
+4.8%
6 Month
-29.7%
-29.7%
1 Year
-32.3%
-32.3%

More News

Read More
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
Looking Into Kezar Life Sciences's Recent Short Interest
Via Benzinga
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate
Via Benzinga
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
From Glancy Prongay & Murray LLP
Via Business Wire
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
From Kezar Life Sciences
Via Business Wire
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
Via Benzinga
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
From Kezar Life Sciences
Via Business Wire
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
From Kezar Life Sciences, Inc.
Via Business Wire
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
From Kezar Life Sciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Saratoga Investment Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths
Via Benzinga
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
From Kezar Life Sciences, Inc.
Via Business Wire

Frequently Asked Questions

Is Kezar Life Sciences, Inc. - Common Stock publicly traded?
Yes, Kezar Life Sciences, Inc. - Common Stock is publicly traded.
What exchange does Kezar Life Sciences, Inc. - Common Stock trade on?
Kezar Life Sciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kezar Life Sciences, Inc. - Common Stock?
The ticker symbol for Kezar Life Sciences, Inc. - Common Stock is KZR on the Nasdaq Stock Market
What is the current price of Kezar Life Sciences, Inc. - Common Stock?
The current price of Kezar Life Sciences, Inc. - Common Stock is 4.350
When was Kezar Life Sciences, Inc. - Common Stock last traded?
The last trade of Kezar Life Sciences, Inc. - Common Stock was at 07/18/25 04:00 PM ET
What is the market capitalization of Kezar Life Sciences, Inc. - Common Stock?
The market capitalization of Kezar Life Sciences, Inc. - Common Stock is 314.97M
How many shares of Kezar Life Sciences, Inc. - Common Stock are outstanding?
Kezar Life Sciences, Inc. - Common Stock has 315M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.